An almost $1-billion vaccine manufacturing facility officially opened in Toronto on Wednesday, with Ontario Premier Doug Ford joining representatives from global biopharmaceutical company Sanofi to inaugurate the new 263,000-square-foot facility near Dufferin and Steeles.
The massive new Charles Best building — named for the American-Canadian medical scientist who co-discovered insulin in Toronto — joins Sanofi's historic Connaught Campus, already a major employer in North York, and introduces another 300 jobs to the site.
First announced in 2021, the $925-million facility is now the largest of its kind among Sanofi's Canadian operations, and will be used as a central hub for the manufacturing, formulation, filling and packaging of the company's Fluzone High-Dose Influenza Vaccine, used to inoculate seniors aged 65 and up.
The project received a $55 million investment from the Province of Ontario, and Premier Ford thanked Sanofi on Wednesday for its "vote of confidence in Ontario and our world-class workers."
In a press release, the province hails the project as "a critical opportunity for Ontario's domestic biomanufacturing capacity, reinforcing its leadership in both seasonal vaccine production and future pandemic response efforts."
The inauguration of the new vaccine plant follows Sanofi's 2024 opening of another $800 million biomanufacturing facility in Toronto — adding up to more than $2 billion in investment province-wide.
Sylvia Jones, Ontario's Deputy Premier and Minister of Health, said that the new facility will "ensure patients always have access to high-quality influenza vaccines and bolster Ontario's position as a global leader for biomanufacturing and vaccine innovation."
James Guy, Canada Country Lead at Sanofi, says that Wednesday's opening "marks a strategic milestone for Sanofi and we remain committed to working with the government to ensure Canadians have timely and reliable access to the innovations that improve — and save — lives."
Sanofi